TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01242683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vivamos Activos Fair Oaks Program
Description: Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vivamos Activos Fair Oaks Program
Description: Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Vivamos Activos Fair Oaks Program
Description: Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms.
Study: NCT03327454

Intervention type: BIOLOGICAL
Intervention: Benepali
Description: Administered as specified in the treatment arm.
Study: NCT00767949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iSONEP
Description: single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
Study: NCT03404427

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Normal sleep night
Description: Usual hours of sleep

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleepless night
Description: Total sleep deprivation the first night
Study: NCT01460368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally
Study: NCT04650776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat strain
Description: The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat strain
Description: The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
Study: NCT01517685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic flax seed oil
Description: 2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: 5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
Study: NCT03310619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Gene modified autologous T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Gene modified autologous T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Gene modified autologous T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Gene modified autologous T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Gene modified autologous T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Pleiotropic Pathway Modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab
Study: NCT02269046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and moxibustion
Description: Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 10mg/d,p.o,12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Change
Description: * Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyle Change
Description: * Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Lifestyle Change
Description: * Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity
Study: NCT03310619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study: NCT04386031

Intervention type: DIAGNOSTIC_TEST
Intervention: Throat culture for fungal pathogens
Description: Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation

Intervention type: DIAGNOSTIC_TEST
Intervention: Throat culture for fungal pathogens
Description: Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
Study: NCT01820156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Respiratory Polygraphy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Respiratory Polygraphy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Polysomnography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Polysomnography
Study: NCT01977937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 250mg/5mL NDC:59762-5025-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simple Syrup
Study: NCT03503136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, nedaplatin, and capecitabine
Description: Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin
Description: Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin
Description: Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
Study: NCT03924284

Intervention type: DIAGNOSTIC_TEST
Intervention: PB2 gene RT-PCR; NS gene RT-PCR
Description: PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
Study: NCT03503136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, and fluorouracil
Description: Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study: NCT03310619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: CC-99282
Study: NCT00137202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (Zofran)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine (Benadryl)
Study: NCT01257191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Black
Description: source: commercial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust Particles
Description: source: diesel engine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fine Concentrated Ambient Particles
Description: source: concentrated ambient air

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrafine Concentrated Ambient Particles
Description: source: concentrated ambient air

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline solution
Study: NCT03424980

Intervention type: COMBINATION_PRODUCT
Intervention: Tyrosine kinase inhibitors
Description: Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
Study: NCT00957216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: placebo: 2 wafers 4 times a day
Study: NCT03503136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
Study: NCT04423393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection or intravenous infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
Study: NCT02867839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus S-1
Description: 8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 only
Description: 16 cycles of adjuvant chemotherapy with S-1 only
Study: NCT00957216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 300mg wafers; 2 wafers 4 times a day
Study: NCT04489017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA-LUT
Description: PEA-LUT administration at the oral dosage of 700 mg x 2/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO administration at the oral dosage of 700 mg x 2/day
Study: NCT04202458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial tenecteplase administration
Description: Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
Study: NCT03078478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: For subcutaneous (s.c., under the skin) injection once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: For subcutaneous (s.c., under the skin) injection once daily
Study: NCT03302065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Study: NCT04187924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic drainage
Description: Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
Study: NCT03302065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Study: NCT02496312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of Apathy Close to Real Life Situation
Description: Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
Study: NCT04187924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX + Autogenic drainage
Description: SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
Study: NCT01857206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mammalian cell based flu vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg based flu vaccine
Study: NCT01117844

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
Study: NCT00949039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isolated pelvis perfusion
Description: injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: chemotherapy and/or radiotherapy and/or surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study: NCT01653314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megavec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megavec

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glivec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glivec
Study: NCT03344705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T
Description: All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Two days before cell infusion,all patients will be treated with fludarabine for 3 days
Study: NCT03344705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
Study: NCT02834741

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NYX-2925
Description: NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NYX-2925
Description: NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
Study: NCT03510715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Pharmaceutical form: capsule,~Route of administration: oral
Study: NCT03503136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, and capecitabine
Description: Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, nedaplatin, and fluorouracil
Description: Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study: NCT00828854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat 5 mg PO every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor (AI) Therapy
Description: AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
Study: NCT01094756

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal replacements, psychotherapy, dietary education
Description: After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
Study: NCT02321631

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-enriched supplement
Description: EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard formula supplement
Description: The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
Study: NCT03029429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: oral theophylline
Study: NCT02288351

Intervention type: OTHER
Group type: OTHER
Intervention: Mix Nutrient Meal
Description: Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
Study: NCT03029429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebo
Study: NCT01021579

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin plus Placebo
Description: PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metfomin plus Simvastatin
Study: NCT04669327

Intervention type: OTHER
Intervention: gait analysis
Description: Vicon nexus with MTI force plate form

Intervention type: OTHER
Intervention: gait analysis
Description: Vicon nexus with MTI force plate form
Study: NCT04215250

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: andropulous method
Description: Counts the CVC depth using specific equation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG
Description: Using ECG to monitor the insertion of the CVC
Study: NCT01369160

Intervention type: BEHAVIORAL
Intervention: Quality of Life measures
Description: measuring QOL with different therapies

Intervention type: BEHAVIORAL
Intervention: Quality of Life measures
Description: measuring QOL with different therapies

Intervention type: BEHAVIORAL
Intervention: Quality of Life measures
Description: measuring QOL with different therapies

Intervention type: BEHAVIORAL
Intervention: Quality of Life measures
Description: measuring QOL with different therapies
Study: NCT01469624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
Study: NCT01222884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer
Description: Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
Study: NCT04465890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22
Description: 200mg/1ml/1bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22
Description: 200mg/1ml/1bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22
Description: 200mg/1ml/1bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22
Description: 200mg/1ml/1bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22
Description: 200mg/1ml/1bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22
Description: 200mg/1ml/1bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 90mg/10ml/1 bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 90mg/10ml/1 bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 90mg/10ml/1 bottle
Study: NCT03904719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus JS001
Description: CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Study: NCT01222884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics